Precigen Inc

Precigen shares have climbed 52.5% over the past three months, outpacing a 0.2% decline for the industry, on the strength of its sole marketed drug, Papzimeos. Papzimeos, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis, generated $74.6 million in revenue in the first six months of 2026, with second-quarter product sales more than doubling sequentially. A marketing authorization application for Papzimeos in adults with recurrent respiratory papillomatosis is under review in Europe, and the drug holds seven years of FDA market exclusivity through Aug. 14, 2032. Inovio Pharmaceuticals is developing INO-3107 as a competing treatment for recurrent respiratory papillomatosis, with an FDA decision expected on Oct. 30, 2026. Beyond Papzimeos, Precigen is developing PRGN-2009 through its AdenoVerse platform, which recently received FDA platform technology designation, and a phase II study is testing PRGN-2009 with Merck's Keytruda in recurrent or metastatic cervical cancer, with a portfolio update planned by the end of 2026.

The United States Food and Drug Administration granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The designation and the earlier PAPZIMEOS approval have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a three-year total shareholder return exceeding 4x, while the more recent 90-day share price return of 32.25% indicates momentum has been building. The stock last closed at $7.75, and the most followed analyst view puts fair value at $11, framing the rally as only a partial catch up. On that view, bearish analysts expect earnings to reach $253.7 million, or $0.68 per share, by about August 2029, up from $336.7 million of losses today, while more bullish analysts expect earnings as high as $363.7 million. On a sales-based measure, the stock trades at 32.4x sales against a US Biotechs group average closer to 12.1x and a fair ratio of 9.5x, a gap that points to valuation risk if sentiment or forecasts change.

Precigen has received FDA platform technology designation for its AdenoVerse immunotherapeutic platform, a move management says could benefit the investigational candidate PRGN-2009 across multiple HPV-associated cancers, including cervical and oropharyngeal cancers. PRGN-2009 is being evaluated in a multicenter phase II study in combination with Merck's Keytruda in patients with recurrent or metastatic cervical cancer, and Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026. The designation comes as Precigen's commercial-stage Papzimeos, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis, generated $74.6 million in revenues in the first six months of 2026, with product revenues more than doubling sequentially in the second quarter. A marketing authorization application for Papzimeos in adults with recurrent respiratory papillomatosis is under review in Europe, and the drug holds seven years of FDA market exclusivity through Aug. 14, 2032. Rival Inovio Pharmaceuticals is developing INO-3107 for recurrent respiratory papillomatosis, with an FDA decision expected on Oct. 30, 2026.

Precigen's sole marketed drug Papzimeos generated $74.6 million in revenues during the first six months of 2026, with second-quarter sales more than doubling sequentially. Papzimeos is the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis, and management said demand continued to grow as the third quarter progressed. The company's marketing authorization application for Papzimeos in Europe is under review, and the drug holds seven years of FDA market exclusivity through Aug. 14, 2032. Rival Inovio Pharmaceuticals is developing INO-3107 for RRP, with an FDA decision expected on Oct. 30, 2026. Precigen also plans to update on its AdenoVerse portfolio, including PRGN-2009 in a phase II study with Merck's Keytruda, by the end of 2026.

Precigen reported second-quarter 2026 financial results that exceeded analyst expectations. The company posted GAAP earnings per share of $0.05, beating estimates by $0.06. Revenue reached $54.98 million, surpassing forecasts by $27.15 million. The results were highlighted by accelerating momentum for Papzimeos.

Precigen Inc. shares surged 11.62 percent to close at $5.38 on Monday, extending a two-day rally as investors reacted to the FDA's grant of six-year orphan drug exclusivity for its recurrent respiratory papillomatosis therapy, Papzimeos. The exclusivity, which runs through August 14, 2032, covers a rare disease affecting fewer than 200,000 people in the United States. President and CEO Helen Sabzevari said the protection, combined with the company's patent portfolio, strengthens market protection and long-term revenue potential.